(Q46202090)

20 December 2017

meta-analysis

0 references

title

A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis (English)

1 reference

20 December 2017

1 reference

J W Mandema

1

1 reference

20 December 2017

D H Salinger

series ordinal

2

1 reference

20 December 2017

S W Baumgartner

series ordinal

3

1 reference

20 December 2017

M A Gibbs

series ordinal

4

1 reference

20 December 2017

language of work or name

English

0 references

publication date

2 November 2011

1 reference

20 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

20 December 2017

volume

90

1 reference

20 December 2017

issue

6

1 reference

20 December 2017

page(s)

828-835

1 reference

20 December 2017

Use of indirect and mixed treatment comparisons for technology assessment

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.256

Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.256

Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.256

Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain--results of a model-based meta-analysis that accounts for encapsulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.256

Model-based development of gemcabene, a new lipid-altering agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.256

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.256

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.256

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.256

Comparison of the efficacy of the tumour necrosis factor blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.256

inferred from DOI database lookup

7 January 2021

based on heuristic

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group st

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.256

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2011.256

1 reference

20 December 2017

1 reference

20 December 2017